# Triple-Targeting T-Cell Engager Aims to Kill the Plasma Cells Other Therapies Spare

- slug: triple-targeting-t-cell-engager-aims-to-kill-the-plasma-cells-other-therapies-spare
- date: 2026-03-25
- category: Biotech & Life Sciences

Kali Therapeutics' experimental drug KT501 entered human testing on March 18, 2026 — the first patient dosed in a Phase Ia study in rheumatoid arthritis — and within hours, Sanofi confirmed it had secured the worldwide license.

---